(LIN) Linde Ordinary Shares - Overview
Exchange: NASDAQ •
Country: United Kingdom •
Currency: USD •
Type: Common Stock •
ISIN: IE000S9YS762
Stock:
Total Rating 55
Risk 70
Buy Signal 0.56
| Risk 5d forecast | |
|---|---|
| Volatility | 18.6% |
| Relative Tail Risk | -2.30% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.46 |
| Alpha | 2.58 |
| Character TTM | |
|---|---|
| Beta | 0.386 |
| Beta Downside | 0.537 |
| Drawdowns 3y | |
|---|---|
| Max DD | 19.18% |
| CAGR/Max DD | 0.71 |
EPS (Earnings per Share)
Revenue
Description: LIN Linde Ordinary Shares
Linde plc operates as an industrial gas company in the United States, China, Germany, the United Kingdom, Australia, Mexico, Brazil, and internationally. It offers atmospheric gases, including oxygen, nitrogen, argon, and rare gases; and process gases, such as hydrogen, helium, carbon dioxide, carbon monoxide, electronic gases, specialty gases, acetylene, etc. The company also designs and constructs turnkey process plants for third-party customers, as well as for the gas businesses in various locations consist of air separation, hydrogen, synthesis, olefin, and natural gas plants. It serves a range of industries comprising healthcare, chemicals and energy, manufacturing, metals and mining, food and beverage, and electronics. Linde plc was founded in 1879 and is based in Woking, the United Kingdom.
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income: 6.94b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA -0.28 > 1.0 |
| NWC/Revenue: -5.51% < 20% (prev -4.84%; Δ -0.67% < -1%) |
| CFO/TA 0.12 > 3% & CFO 10.35b > Net Income 6.94b |
| Net Debt (21.93b) to EBITDA (12.85b): 1.71 < 3 |
| Current Ratio: 0.88 > 1.5 & < 3 |
| Outstanding Shares: last quarter (468.7m) vs 12m ago -2.12% < -2% |
| Gross Margin: 43.33% > 18% (prev 0.37%; Δ 4296 % > 0.5%) |
| Asset Turnover: 40.71% > 50% (prev 41.18%; Δ -0.47% > 0%) |
| Interest Coverage Ratio: 33.41 > 6 (EBITDA TTM 12.85b / Interest Expense TTM 272.0m) |
Altman Z'' 1.45
| A: -0.02 (Total Current Assets 13.32b - Total Current Liabilities 15.20b) / Total Assets 86.82b |
| B: 0.19 (Retained Earnings 16.61b / Total Assets 86.82b) |
| C: 0.11 (EBIT TTM 9.09b / Avg Total Assets 83.48b) |
| D: 0.22 (Book Value of Equity 10.38b / Total Liabilities 47.08b) |
| Altman-Z'' Score: 1.45 = BB |
Beneish M -3.18
| DSRI: 1.00 (Receivables 5.24b/5.06b, Revenue 33.99b/33.01b) |
| GMI: 0.84 (GM 43.33% / 36.61%) |
| AQI: 1.01 (AQ_t 0.52 / AQ_t-1 0.52) |
| SGI: 1.03 (Revenue 33.99b / 33.01b) |
| TATA: -0.04 (NI 6.94b - CFO 10.35b) / TA 86.82b) |
| Beneish M-Score: -3.18 (Cap -4..+1) = AA |
What is the price of LIN shares?
As of March 02, 2026, the stock is trading at USD 508.08 with a total of 3,201,819 shares traded.
Over the past week, the price has changed by +1.99%, over one month by +10.41%, over three months by +25.25% and over the past year by +11.39%.
Over the past week, the price has changed by +1.99%, over one month by +10.41%, over three months by +25.25% and over the past year by +11.39%.
Is LIN a buy, sell or hold?
Linde Ordinary Shares has received a consensus analysts rating of 4.00.
Therefore, it is recommended to buy LIN.
- StrongBuy: 12
- Buy: 6
- Hold: 9
- Sell: 0
- StrongSell: 1
What are the forecasts/targets for the LIN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 512.4 | 0.9% |
| Analysts Target Price | 512.4 | 0.9% |
LIN Fundamental Data Overview February 28, 2026
P/E Trailing = 34.1212
P/E Forward = 26.0417
P/S = 6.878
P/B = 5.7158
P/EG = 2.1857
Revenue TTM = 33.99b USD
EBIT TTM = 9.09b USD
EBITDA TTM = 12.85b USD
Long Term Debt = 18.59b USD (from longTermDebt, two quarters ago)
Short Term Debt = 6.31b USD (from shortTermDebt, last quarter)
Debt = 26.99b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 21.93b USD (from netDebt column, last quarter)
Enterprise Value = 255.69b USD (233.76b + Debt 26.99b - CCE 5.06b)
Interest Coverage Ratio = 33.41 (Ebit TTM 9.09b / Interest Expense TTM 272.0m)
EV/FCF = 50.24x (Enterprise Value 255.69b / FCF TTM 5.09b)
FCF Yield = 1.99% (FCF TTM 5.09b / Enterprise Value 255.69b)
FCF Margin = 14.97% (FCF TTM 5.09b / Revenue TTM 33.99b)
Net Margin = 20.42% (Net Income TTM 6.94b / Revenue TTM 33.99b)
Gross Margin = 43.33% ((Revenue TTM 33.99b - Cost of Revenue TTM 19.26b) / Revenue TTM)
Gross Margin QoQ = 48.12% (prev 38.02%)
Tobins Q-Ratio = 2.95 (Enterprise Value 255.69b / Total Assets 86.82b)
Interest Expense / Debt = 0.24% (Interest Expense 64.0m / Debt 26.99b)
Taxrate = 23.92% (481.0m / 2.01b)
NOPAT = 6.91b (EBIT 9.09b * (1 - 23.92%))
Current Ratio = 0.88 (Total Current Assets 13.32b / Total Current Liabilities 15.20b)
Debt / Equity = 0.71 (Debt 26.99b / totalStockholderEquity, last quarter 38.24b)
Debt / EBITDA = 1.71 (Net Debt 21.93b / EBITDA 12.85b)
Debt / FCF = 4.31 (Net Debt 21.93b / FCF TTM 5.09b)
Total Stockholder Equity = 38.35b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.31% (Net Income 6.94b / Total Assets 86.82b)
RoE = 18.10% (Net Income TTM 6.94b / Total Stockholder Equity 38.35b)
RoCE = 15.96% (EBIT 9.09b / Capital Employed (Equity 38.35b + L.T.Debt 18.59b))
RoIC = 10.87% (NOPAT 6.91b / Invested Capital 63.63b)
WACC = 6.60% (E(233.76b)/V(260.75b) * Re(7.34%) + D(26.99b)/V(260.75b) * Rd(0.24%) * (1-Tc(0.24)))
Discount Rate = 7.34% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -2.02%
[DCF] Terminal Value 82.96% ; FCFF base≈5.02b ; Y1≈4.81b ; Y5≈4.67b
[DCF] Fair Price = 196.7 (EV 113.79b - Net Debt 21.93b = Equity 91.86b / Shares 466.9m; r=6.60% [WACC]; 5y FCF grow -5.61% → 2.90% )
EPS Correlation: 96.79 | EPS CAGR: 10.08% | SUE: 0.05 | # QB: 0
Revenue Correlation: 30.07 | Revenue CAGR: 1.75% | SUE: 0.76 | # QB: 0
EPS next Quarter (2026-06-30): EPS=4.45 | Chg7d=+0.002 | Chg30d=+0.004 | Revisions Net=-1 | Analysts=17
EPS current Year (2026-12-31): EPS=17.83 | Chg7d=+0.007 | Chg30d=+0.004 | Revisions Net=+2 | Growth EPS=+8.3% | Growth Revenue=+4.6%
EPS next Year (2027-12-31): EPS=19.48 | Chg7d=+0.004 | Chg30d=-0.098 | Revisions Net=+3 | Growth EPS=+9.2% | Growth Revenue=+5.0%
[Analyst] Revisions Ratio: -0.11 (4 Up / 5 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 5.0% (Discount Rate 7.9% - Earnings Yield 2.9%)
[Growth] Growth Spread = -0.3% (Analyst 4.7% - Implied 5.0%)
P/E Forward = 26.0417
P/S = 6.878
P/B = 5.7158
P/EG = 2.1857
Revenue TTM = 33.99b USD
EBIT TTM = 9.09b USD
EBITDA TTM = 12.85b USD
Long Term Debt = 18.59b USD (from longTermDebt, two quarters ago)
Short Term Debt = 6.31b USD (from shortTermDebt, last quarter)
Debt = 26.99b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 21.93b USD (from netDebt column, last quarter)
Enterprise Value = 255.69b USD (233.76b + Debt 26.99b - CCE 5.06b)
Interest Coverage Ratio = 33.41 (Ebit TTM 9.09b / Interest Expense TTM 272.0m)
EV/FCF = 50.24x (Enterprise Value 255.69b / FCF TTM 5.09b)
FCF Yield = 1.99% (FCF TTM 5.09b / Enterprise Value 255.69b)
FCF Margin = 14.97% (FCF TTM 5.09b / Revenue TTM 33.99b)
Net Margin = 20.42% (Net Income TTM 6.94b / Revenue TTM 33.99b)
Gross Margin = 43.33% ((Revenue TTM 33.99b - Cost of Revenue TTM 19.26b) / Revenue TTM)
Gross Margin QoQ = 48.12% (prev 38.02%)
Tobins Q-Ratio = 2.95 (Enterprise Value 255.69b / Total Assets 86.82b)
Interest Expense / Debt = 0.24% (Interest Expense 64.0m / Debt 26.99b)
Taxrate = 23.92% (481.0m / 2.01b)
NOPAT = 6.91b (EBIT 9.09b * (1 - 23.92%))
Current Ratio = 0.88 (Total Current Assets 13.32b / Total Current Liabilities 15.20b)
Debt / Equity = 0.71 (Debt 26.99b / totalStockholderEquity, last quarter 38.24b)
Debt / EBITDA = 1.71 (Net Debt 21.93b / EBITDA 12.85b)
Debt / FCF = 4.31 (Net Debt 21.93b / FCF TTM 5.09b)
Total Stockholder Equity = 38.35b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.31% (Net Income 6.94b / Total Assets 86.82b)
RoE = 18.10% (Net Income TTM 6.94b / Total Stockholder Equity 38.35b)
RoCE = 15.96% (EBIT 9.09b / Capital Employed (Equity 38.35b + L.T.Debt 18.59b))
RoIC = 10.87% (NOPAT 6.91b / Invested Capital 63.63b)
WACC = 6.60% (E(233.76b)/V(260.75b) * Re(7.34%) + D(26.99b)/V(260.75b) * Rd(0.24%) * (1-Tc(0.24)))
Discount Rate = 7.34% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -2.02%
[DCF] Terminal Value 82.96% ; FCFF base≈5.02b ; Y1≈4.81b ; Y5≈4.67b
[DCF] Fair Price = 196.7 (EV 113.79b - Net Debt 21.93b = Equity 91.86b / Shares 466.9m; r=6.60% [WACC]; 5y FCF grow -5.61% → 2.90% )
EPS Correlation: 96.79 | EPS CAGR: 10.08% | SUE: 0.05 | # QB: 0
Revenue Correlation: 30.07 | Revenue CAGR: 1.75% | SUE: 0.76 | # QB: 0
EPS next Quarter (2026-06-30): EPS=4.45 | Chg7d=+0.002 | Chg30d=+0.004 | Revisions Net=-1 | Analysts=17
EPS current Year (2026-12-31): EPS=17.83 | Chg7d=+0.007 | Chg30d=+0.004 | Revisions Net=+2 | Growth EPS=+8.3% | Growth Revenue=+4.6%
EPS next Year (2027-12-31): EPS=19.48 | Chg7d=+0.004 | Chg30d=-0.098 | Revisions Net=+3 | Growth EPS=+9.2% | Growth Revenue=+5.0%
[Analyst] Revisions Ratio: -0.11 (4 Up / 5 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 5.0% (Discount Rate 7.9% - Earnings Yield 2.9%)
[Growth] Growth Spread = -0.3% (Analyst 4.7% - Implied 5.0%)